Anti-LMW Kininogen antibody (Biotin) (ab79651)

Overview

  • Product nameAnti-LMW Kininogen antibody (Biotin)
    See all LMW Kininogen primary antibodies
  • Description
    Rabbit polyclonal to LMW Kininogen (Biotin)
  • ConjugationBiotin
  • Tested applicationsWB, IP, ELISA, RIAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Kininogen (LMW) purified from human plasma

Properties

Applications

Our Abpromise guarantee covers the use of ab79651 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 20 µg/ml. Predicted molecular weight: 48 kDa.
IP Use at an assay dependent dilution.
ELISA Use a concentration of 4 - 10 µg/ml.
RIA Use a concentration of 4 - 10 µg/ml.

Target

  • Function(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
  • Tissue specificitySecreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.
  • Involvement in diseaseDefects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) [MIM:228960]. HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.
  • Sequence similaritiesContains 3 cystatin kininogen-type domains.
  • Post-translational
    modifications
    Bradykinin is released from kininogen by plasma kallikrein.
    Hydroxylation of Pro-383 occurs prior to the release of bradykinin.
    Phosphorylation sites are present in the extracellular medium.
    N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
  • Cellular localizationSecreted > extracellular space.
  • Information by UniProt
  • Database links
  • Alternative names
    • Alpha-2-thiol proteinase inhibitor antibody
    • BDK antibody
    • BK antibody
    • Fitzgerald factor antibody
    • High molecular weight kininogen antibody
    • HMWK antibody
    • Ile-Ser-Bradykinin antibody
    • Kallidin I antibody
    • Kallidin II antibody
    • Kininogen 1 antibody
    • KNG antibody
    • KNG1 antibody
    • KNG1_HUMAN antibody
    • LMW antibody
    • Low molecular weight growth promoting factor antibody
    • Low molecular weight growth-promoting factor antibody
    • Low molecular weight kininogen antibody
    • Williams-Fitzgerald-Flaujeac factor antibody
    see all

References for Anti-LMW Kininogen antibody (Biotin) (ab79651)

ab79651 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab79651.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"